Adding Antiplatelet During Edoxaban Treatment in Stroke Patients With Non-valvular Atrial Fibrillation (ADD-ON)

Active, not recruitingOBSERVATIONAL
Enrollment

1,200

Participants

Timeline

Start Date

October 8, 2019

Primary Completion Date

June 27, 2025

Study Completion Date

June 27, 2026

Conditions
Acute Ischemic StrokeAtrial FibrillationExtracranial AtherosclerosisIntracranial AtherosclerosisCoronary Artery AtherosclerosisPeripheral Artery StenosisAnticoagulantAntiplatelet
Interventions
DRUG

Edoxaban Monotherapy

when the patients will be initially registered in this study, duty physicians will make a decision to give additional antiplatelet therapy in addition to standard edoxaban therapy.

Trial Locations (1)

138-736

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
collaborator

Samsung Medical Center

OTHER

collaborator

Myongji Hospital

OTHER

collaborator

Ewha Womans University

OTHER

collaborator

Chonbuk National University

OTHER

collaborator

Pusan National University Hospital

OTHER

collaborator

Korea University Ansan Hospital

OTHER

collaborator

Keimyung University Dongsan Medical Center

OTHER

collaborator

Chonnam National University Hospital

OTHER

collaborator

Korea University Guro Hospital

OTHER

collaborator

Chungnam National University Hospital

OTHER

collaborator

Chung-Ang University Hosptial, Chung-Ang University College of Medicine

OTHER

collaborator

Kyungpook National University Hospital

OTHER

collaborator

Dongtan Sacred Heart Hospital

OTHER

collaborator

Eulji University Hospital

OTHER

lead

Asan Medical Center

OTHER